Kaempferide
Based on 7 publication(s) in Google Scholar
Kaempferide is an orally active flavonol isolated from Hippophae rhamnoides L. Kaempferide has anticancer, anti-inflammatory, antioxidant, antidiabetic, antiobesity, antihypertensive, and neuroprotective activities. Kaempferide induces apoptosis. Kaempferide promotes osteogenesis through antioxidants and can be used in osteoporosis research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.80%
- CAS No.: 491-54-3
- 화학식: C16H12O6
- 분자량:300.26
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Kaempferide
More- Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]
- Food Chem. 2025 Dec 30:497:146992. [Abstract]
- Food Chem. 2025 Oct 15:489:144992. [Abstract]
- Ind Crops Prod. 2025 Dec 11;239:122458.
- Int Immunopharmacol. 2026 Jun 15:179:116601. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Evid Based Complement Alternat Med. 2021 Aug 26:2021:7169211. [Abstract]
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
2.2 x 10-5 M
Compound: 13
|
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
|
[PMID: 20619940] |
| B16 | IC50 |
16 μM
Compound: 5
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs
|
[PMID: 19615910] |
| B16-4A5 | IC50 |
>100 μM
Compound: 5
|
Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability after 68 hrs by WST8 assay
Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability after 68 hrs by WST8 assay
|
[PMID: 19615910] |
| HeLa | IC50 |
2 μg/mL
Compound: 7
|
Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA
Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA
|
[PMID: 19942440] |
| HeLa | IC50 |
2.3 x 10-5 M
Compound: 13
|
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
|
[PMID: 20619940] |
| HT-1080 | ED50 |
<8 μg/mL
Compound: Kaempferide
|
Cytotoxicity against human HT1080 cells by MTT assay
Cytotoxicity against human HT1080 cells by MTT assay
|
[PMID: 11000036] |
| HT-1080 | ED50 |
2.91 μg/mL
Compound: 20
|
Cytotoxicity against human HT1080 cells after 24 hrs by MTT assay
Cytotoxicity against human HT1080 cells after 24 hrs by MTT assay
|
[PMID: 9677271] |
| HT-29 | IC50 |
3.2 x 10-5 M
Compound: 13
|
Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
|
[PMID: 20619940] |
| Huh-7 | CC50 |
>50 μM
Compound: 30
|
Cytotoxicity against human Huh7.5.1 cells by MTT assay
Cytotoxicity against human Huh7.5.1 cells by MTT assay
|
[PMID: 22445328] |
| KB | ED50 |
20 μg/mL
Compound: NSC-407294
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 469554] |
| L929 | EC50 |
129 μM
Compound: kaempferide
|
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
|
[PMID: 9287415] |
| L929 | EC50 |
140 μM
Compound: kaempferide
|
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
|
[PMID: 9287415] |
| Monocyte | IC50 |
5.7 μM
Compound: kaempferide
|
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
|
[PMID: 8882428] |
| Monocyte | IC50 |
5.7 x 10-6 M
Compound: kaempferide
|
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
|
[PMID: 8882428] |
Kaempferid is toxic in HCC cell lines (HepG2:IC50 = 27.94 µM; Huh7: IC50 = 25.65 µM; N1S1: IC50 = 15.18 µM)[1].
Kaempferid (5, 20 μM; 48 h) reduces lipid accumulation and oxidative stress in HepG2 cells induced by oral acid (OA) (0.5 mM) (HY-N1446)[2].
Kaempferide promotes osteogenesis through the FoxO1/β-catenin signaling pathway [3].
Kaempferide (10-15 μM; 24 h) is toxic in HeLa cells with an IC50 of 16 μM and can induce apoptosis[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2
-
Concentration:5 μM, 10 μM, 20 μM . Before treatment with OA (HY-N1446) (0.5 mM; 48 h)
-
Incubation Time:48 h
-
Result:Lowered the expression of proteins related to fat production, including sterol regulatory element-binding protein 1 (SREBP1), fatty acid synthase (FAS), and stearoyl-CoA desaturase 1 (SCD-1).
Reduced the expression of two adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT enhancer-binding protein β (C/EBPβ).
Enhanced the expression of heme oxygenase-1 (HO-1) and nuclear factor erythroid 2-related factor 2 (Nrf2).
Kaempferide (0.1-0.3 mg/kg; injection, single dose) alleviates myocardial ischemia/reperfusion injury by activating PI3K/Akt/GSK-3β pathway in Sprague Dawley (I/R)-induced rats[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:High-fat diet male C57BL/6J mice model[4]
-
Dosage:10 mg/kg
-
Administration:Supplemented in daily diet, once daily for16 weeks
-
Result:Reduced the weight, organ weight, and index of mice.
Lowered the levels of glycolipids in mouse serum.
Decreased the expression levels of inflammatory-related genes, including NF-κB, IL-6, ICAM-1, VCAM-1, and TNF-α.
-
Animal Model:Ischemia/Reperfusion (I/R) SD rat model[5].
-
Dosage:0.1 mg/kg, 0.3 mg/kg, 3 mg/kg
-
Administration:Injection, Single dose. Before the I/R injury induced by Coronary Artery Ligation (CAL) in SD rats.
-
Result:Significantly improved heart function, reduced myocardial injury by reducing myocardial enzyme levels, and dose-dependently reduced the area of myocardial infarction in rats.
Significantly decreased serum levels of TNF-α, IL-6, C-reactive protein (CRP), MDA, and ROS, while increasing serum levels of SOD.
Downregulated the expression levels of nuclear factor erythroid 2-related factor 2 (Nrf2) and cleaved caspase-3, and upregulated the phosphorylation expression levels of phospho-Akt (p-Akt) and phospho-glycogen synthase kinase-3β (p-GSK-3β).
Chemical Information
-
CAS No. 491-54-3
-
Appearance Solid
-
분자량 300.26
-
화학식 C16H12O6
-
Color Light yellow to yellow
-
SMILES
O=C1C(O)=C(C2=CC=C(OC)C=C2)OC3=CC(O)=CC(O)=C13
-
Synonyms
Kaempferol 4'-O-methyl ether
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]2021 Jan;11(1):143-155. PMID: 33532186 -
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 Oct 15:489:144992. PMID: 40466530 -
-
Int Immunopharmacol
Kaempferide alleviates glucocorticoid-induced osteoporosis by targeting ferroptosis through the GSK3β/Nrf-2/GPX4 pathway. [Abstract]2026 Jun 15:179:116601. PMID: 41962468 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Evid Based Complement Alternat Med
Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation. [Abstract]2021 Aug 26:2021:7169211. PMID: 34484402
용액&용해도
DMSO : 20 mg/mL (66.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2 mg/mL (6.66 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (282 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[2]. Tie F, et al. Kaempferol and kaempferide attenuate oleic acid-induced lipid accumulation and oxidative stress in HepG2 cells[J]. International Journal of Molecular Sciences, 2021, 22(16): 8847. [Content Brief]
[3]. Ma X, et al. Kaempferide enhances antioxidant capacity to promote osteogenesis through FoxO1/β-catenin signaling pathway[J]. European Journal of Pharmacology, 2021, 911: 174555. [Content Brief]
[4]. Tang H, et al. Kaempferide improves oxidative stress and inflammation by inhibiting the TLR4/IκBα/NF-κB pathway in obese mice[J]. Iranian Journal of Basic Medical Sciences, 2021, 24(4): 493. [Content Brief]
[5]. Wang D, et al. Kaempferide Protects against Myocardial Ischemia/Reperfusion Injury through Activation of the PI3K/Akt/GSK-3β Pathway. Mediators Inflamm. 2017;2017:5278218. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3304 mL | 16.6522 mL | 33.3045 mL | 83.2612 mL |
| 5 mM | 0.6661 mL | 3.3304 mL | 6.6609 mL | 16.6522 mL | |
| 10 mM | 0.3330 mL | 1.6652 mL | 3.3304 mL | 8.3261 mL | |
| 15 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL | 5.5507 mL | |
| 20 mM | 0.1665 mL | 0.8326 mL | 1.6652 mL | 4.1631 mL | |
| 25 mM | 0.1332 mL | 0.6661 mL | 1.3322 mL | 3.3304 mL | |
| 30 mM | 0.1110 mL | 0.5551 mL | 1.1101 mL | 2.7754 mL | |
| 40 mM | 0.0833 mL | 0.4163 mL | 0.8326 mL | 2.0815 mL | |
| 50 mM | 0.0666 mL | 0.3330 mL | 0.6661 mL | 1.6652 mL | |
| 60 mM | 0.0555 mL | 0.2775 mL | 0.5551 mL | 1.3877 mL |
Kaempferide Related Classifications
HY-15449 Related Classifications
Powered by Bioz
- Kaempferide
- 491-54-3
- Kaempferol 4'-O-methyl ether
- Estrogen Receptor/ERR
- Autophagy
- Bacterial
- Influenza Virus
- Apoptosis
- PI3K
- Akt
- GSK-3
- FOXO
- β-catenin
- HCC
- osteoporosis
- osteogenesis
- antioxidant
- non-alcoholic fatty liver disease (NAFLD)
- HepG2
- HeLa
- Huh7
- N1S1
- apoptosis
- diabetes
- obesity
- hypertension
- neuroprotection
- SD (Sprague Dawley)
- C57BL /6J
- myocardial ischemia/reperfusion injury
- Inhibitor
- inhibitor
- inhibit